phenethyl isothiocyanate has been researched along with Granulocytic Leukemia, Chronic in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chai, Q; Fang, Q; Wang, J; Wang, Y; Wei, S | 1 |
| Mukherjee, A; Mukherjee, S; Roy, M; Sarkar, R | 1 |
| Arlinghaus, RB; Carew, J; Giles, FJ; Huang, P; Keating, MJ; Lu, W; Trachootham, D; Zhang, H | 1 |
3 other study(ies) available for phenethyl isothiocyanate and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Phenethyl isothiocyanate inhibits growth of human chronic myeloid leukemia K562 cells via reactive oxygen species generation and caspases.
Topics: Anticarcinogenic Agents; Apoptosis; Caspase 3; Caspase 9; Caspases; Cell Proliferation; Cytochromes c; Heme Oxygenase-1; Humans; Isothiocyanates; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Reactive Oxygen Species; RNA, Messenger | 2014 |
Inhibition of crosstalk between Bcr-Abl and PKC signaling by PEITC, augments imatinib sensitivity in chronic myelogenous leukemia cells.
Topics: Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Extracellular Signal-Regulated MAP Kinases; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Isothiocyanates; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytes; Molecular Targeted Therapy; Phosphorylation; Protein Kinase C; Proto-Oncogene Proteins c-raf | 2015 |
Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism.
Topics: Aldehyde Dehydrogenase; Animals; Anticarcinogenic Agents; Antineoplastic Agents; Antioxidants; Apoptosis; Benzamides; Caspase 3; Cells, Cultured; Drug Resistance, Neoplasm; Enzyme Activation; Fusion Proteins, bcr-abl; Glutathione; Humans; Imatinib Mesylate; Immunoblotting; Isothiocyanates; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Oxidation-Reduction; Piperazines; Precursor Cells, B-Lymphoid; Protein-Tyrosine Kinases; Pyrimidines; Reactive Oxygen Species | 2008 |